Oncology

#Immuno-oncology #Mouse models #Oncology

Syngeneic mouse models for preclinical immuno-oncology

The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery. Syngeneic models—inbred mice bearing an engrafted tumour derived from a genetically identical mouse strain—are invaluable preclinical research tools that enable tumor studies in the context of a complete and functional immune system. Read More

#Resources

#CAR-T #Oncology #Therapeutics

CAR T-cell therapy highly effective in patients with high-risk non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a Phase III clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. While… Read More

#Cancer Research #News #Videos

#Cellular & Molecular biology #Oncology

Scientists use geometry to track cell migrations with potential impact for cancer research

https://www.ddw-online.com/wp-content/uploads/2020/12/collage.mp4   Cells are constantly moving throughout our bodies, performing functions crucial to tissue development, immune responses and general wellbeing. This locomotion—an essential feature of biological processes, both normal and pathological—is guided by chemical cues long studied by scientists interested in cellular migration. But a team of physicists and… Read More

#Cancer Research #Editor's Choice #News #Videos

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Oncology #Therapeutics

Lantern Pharma AI milestone will cut cost, time and risk in developing new drug therapies

Lantern Pharma has reached a significant milestone by surpassing one billion curated data points on its RADR platform, a total it believes is the most amassed by any company in the biotech sector. The milestone, which was reached well ahead of schedule, enables new opportunities in Lantern’s work to identify and… Read More

#News

#Biotechnology #Oncology #Therapeutics

STORM Therapeutics uses Evotec platform to push oncology project towards clinical studies

STORM Therapeutics will use INDiGO, Evotec’s integrated, accelerated IND-enabling platform, to progress its STC-15 towards an IND application in 2021. STORM, a biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has selected STC-15 as a first-in-class development candidate. STORM discovered STC-15, an orally… Read More

#Cancer Research #News

#Biopharmaceuticals #Oncology #Therapeutics

Merck’s acquisition of VelosBio will boost oncology push

Merck (known as MSD outside the United States and Canada), is paying  $2.75 billion for VelosBio, a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is currently being… Read More

#Cancer Research #News

#Biotechnology #Drug discovery #Drug targets #Hit identification #Immunotherapy #Oncology

Partnership will progress targeted cancer immune therapy drug discovery

APEIRON Biologics, a biotech company developing breakthrough therapies to treat cancer and respiratory conditions, has selected Domainex to provide integrated lead optimisation services in order to advance the development of inhibitors for the E3 ubiquitin ligase Cbl-b through small molecule drug discovery. Under the terms of the agreement, Domainex, an… Read More

#Cancer Research #News

#Cancer research #Oncology

Cancer Research UK collaboration will identify oncology innovation

The national programme, to develop and progress start-up oncology projects, is being launched by Bruntwood SciTech at Alderley Park with funding from Innovate UK and Cancer Research UK A collaboration of global pharmaceutical and healthcare companies, research institutions and public bodies will identify oncology innovations and leverage their combined insight… Read More

#Cancer Research #Editor's Choice #News

#Cancer #Oncology #Precision medicine

Mission Bio launches single-cell multi-omics system for precision cancer therapies

Mission Bio has launched the Tapestri Single-cell Multi-omics Solution – a comprehensive single-cell multi-omics platform. With a new instrument, single-cell multi-omics reagent kits, TotalSeq-D antibody content from BioLegend, and visualisation software, the package provides layered insight into multiple analytes across all blood cancers, reducing drug development time and cost by… Read More

#Cancer Research #News

#Drug development #Drug discovery #Oncology

New drug for difficult-to-drug cancer mutation could be key treatment for other cancers

A new drug designed to counter the effects of an important, but very hard to target, cancer mutation could be effective against a range of tumour types including lung and gynaecological cancers, a new clinical trial shows. Researchers used an innovative, intermittent treatment schedule to limit the drug’s toxicity, and… Read More

#Cancer Research #News #Trending News

#CAR-T #Immunotherapy #Oncology

Collaboration aims to develop targeted, effective cancer immunotherapies

Immunai has joined forces with Baylor College of Medicine to bring more targeted and effective cancer therapies to market. Leveraging Immunai’s single-cell technology and artificial intelligence, Baylor and Immunai will analyse natural killer T (NKT) cells and genetically engineer them into immunotherapies that target a variety of cancers, including solid… Read More

#News